Doctors info

Professional Overview

Dr. Aruna Korlimarla, PhD, is the Principal Scientist and Head of the Department of Molecular Oncology at Sri Shankara Cancer Hospital and Research Centre, with over 15 years of experience in translational cancer research. A pioneer in applying spatial transcriptomics for breast cancer in India, she specializes in precision oncology, molecular diagnostics, and multi-omics cancer research. Her expertise spans advanced platforms including next-generation sequencing, NanoString, qRT-PCR, immunohistochemistry, and bioinformatics-driven multi-omics data integration. Dr. Korlimarla has contributed extensively to biomarker discovery, companion diagnostics development, and clinical implementation of molecular tools to improve patient outcomes. She has authored over 25 peer-reviewed articles and presented 20 abstracts internationally. As a member of the Indian Cancer Genome Atlas and the Association of Molecular Pathologists of India, she is committed to advancing population-specific precision medicine, early detection technologies, and AI-integrated diagnostics. Her vision is to position the institution as a premier precision oncology center in India and South Asia.

Research Publications

1. GENE EXPRESSION BASED STUDY TO IDENTIFY POOR PROGNOSTIC INDICATORS IN CARCINOMA CERVIX

Authors: Jayasingh S, Vadaparty AV, Korlimarla AR

Journal: International Journal of Gynecological Cancer

Published: 2025 Feb 1

Additional Details: 35(2)

2. Breast cancer cell migration is potentiated by associated fibroblasts through a laminin-511-Integrin α6β1-transduced Arp2/3 localization

Authors: Banerjee M, Mishra S, Vinukumar G, Pandhari M, Parimala DM, Sarvothama M, Korlimarla A, Srinath BS, Bhat R

Journal: bioRxiv

Published: 2025 Aug 12

Additional Details: 2025-08

3. The Impact of Breast Cancer on the Patient and the Family in Indian Perspective

Authors: Alexander A, Kaluve R, Prabhu JS, Korlimarla A, Srinath BS, Manjunath S, et al

Journal: Indian journal of palliative care

Published: 2019

Additional Details: 25(1):66-72

4. Prognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer

Authors: Bajaj R, Tripathi R, Sridhar TS, Korlimarla A, Choudhury KD, Suryavanshi M, et al

Journal: PloS one

Published: 2020

Additional Details: 15(11):e0242190

5. Cystic Neutrophilic Granulomatous Mastitis: A Clinicopathological Study With 16s rRNA Sequencing for the Detection of Corynebacteria in Formalin-Fixed Paraffin-Embedded Tissue

Authors: Naik MA, Korlimarla A, Shetty ST, Fernandes AM, Pai SA

Journal: International journal of surgical pathology

Published: 2020

Additional Details: 28(4):371-81

6. miR-18a activates Wnt pathway in ER-positive breast cancer and is associated with poor prognosis.

Authors: Nair MG, Prabhu JS, Korlimarla A, Rajarajan S, P SH, Kaul R, et al.

Journal: Cancer medicine

Published: 2020

Additional Details: 9(15):5587-97

7. Abstract PS6-55: The prognostic utility of AR/ER ratio in young women with breast cancer

Authors: Prabhu JS, Korlimarla A, Rajarajan S, Alexander A, Anupama C, Ramesh R, et al

Journal: Cancer research

Published: 2021

Additional Details: 81(4 Suppl)

8. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes

Authors: Rajarajan S, Korlimarla A, Alexander A, Anupama CE, Ramesh R, Srinath BS, et al

Journal: Frontiers in endocrinology

Published: 2021

Additional Details: 12:679756

9. NGS-based profiling of key cancer genes in Indian triple-negative breast cancer patients reinforces molecular heterogeneity of the disease

Authors: Sahasrabuddhe NA, Korlimarla A, Kulkarni M, Kusuma V, Prabhu JS, Dixit S, et al

Journal: Indian journal of cancer

Published: 2021

Additional Details: 58(4):598-602

10. Prenatal epigenetic factors are predisposing for neurodevelopmental disorders-Considering placenta as a model

Authors: Durbagula S, Korlimarla A, Ravikumar G, Valiya Parambath S, Kaku SM, Visweswariah AM

Journal: Birth defects research

Published: 2022

Additional Details: 114(20):1324-42

11. Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers

Authors: Korlimarla A, Ps H, Prabhu J, Ragulan C, Patil Y, Vp S, et al

Journal: Translational oncology

Published: 2022

Additional Details: 25:101511

12. 405P Matched primary-residual tumor analysis identifies estrogen and immune pathways as resistance mechanisms to neoadjuvant therapy in ER+/HER2+ breast cancer

Authors: Ramesh SN, Mathranda SA, Raj B, Srihari S, Devi D, BS S, Krishna DL, Korlimarla A

Journal: Annals of Oncology

Published: 2025 Sep 1

Additional Details: 36:S370

13. Downregulation of Decorin in ovarian cancer cells and colonization microenvironment drives progression

Authors: Sarkar P, Naha A, Hussain S, Manattayil JK, PS H, Korlimarla A, Vadaparty A, Raghunathan V, Kumar R, Bhat R

Journal: Biointerphases

Published: 2025 Sep 1

Additional Details: 20(5)

14. Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancer

Authors: HP S, Paul L, Veeraiyan D, Narikot A, Veldore V, Tanwar N, Goswami H, Kumar RV, SB S, Korlimarla A

15. Glycation‐Driven Impairment of Cytoskeletal Homeostasis and Viability Disables Glyoxalase‐Low Mesothelia From Resisting Cancer Colonization

Authors: Mishra S, Vidhipriya K, Gopikrishnan A, Sarkar P, Mishra S, Prasanna CV, Hari PS, Korlimarla A, Sen P, Bhat R

Journal: Journal of Cellular Physiology

Published: 2026 Jan

Additional Details: 241(1):e70123

16. MicroRNA-mediated resistance mechanisms in NAT-treated HER2-positive breast cancer (BC): A single centre retrospective analysis from matched primary and residual tumours

Authors: Mathranda SA, Kumar P, Kumar R, Srihari S, Diwaker R, Munirathnam V, Simha V, Anantharamu S, RN S, PS H, Veeraiyan D

17. Complementary Role of Ancillary Tests in Acute Promyelocytic leukemia–A Case Series

Authors: Kulkarni J, Kumari P, Korlimarla A

Journal: Indian Journal of Hematology and Blood Transfusion

Published: 2025 Dec 11

Additional Details: 1-6

18. Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancer

Authors: Tanwar N, Sreekanthreddy P, Goswami H, Kumar RV, Srinath BS, Korlimarla A

Languages Spoken

Kannada English Hindi Telugu

Dr Aruna Korlimarla

Professional Overview

Research Publications

1. GENE EXPRESSION BASED STUDY TO IDENTIFY POOR PROGNOSTIC INDICATORS IN CARCINOMA CERVIX

2. Breast cancer cell migration is potentiated by associated fibroblasts through a laminin-511-Integrin α6β1-transduced Arp2/3 localization

3. The Impact of Breast Cancer on the Patient and the Family in Indian Perspective

4. Prognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer

5. Cystic Neutrophilic Granulomatous Mastitis: A Clinicopathological Study With 16s rRNA Sequencing for the Detection of Corynebacteria in Formalin-Fixed Paraffin-Embedded Tissue

6. miR-18a activates Wnt pathway in ER-positive breast cancer and is associated with poor prognosis.

7. Abstract PS6-55: The prognostic utility of AR/ER ratio in young women with breast cancer

8. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes

9. NGS-based profiling of key cancer genes in Indian triple-negative breast cancer patients reinforces molecular heterogeneity of the disease

10. Prenatal epigenetic factors are predisposing for neurodevelopmental disorders-Considering placenta as a model

11. Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers

12. 405P Matched primary-residual tumor analysis identifies estrogen and immune pathways as resistance mechanisms to neoadjuvant therapy in ER+/HER2+ breast cancer

13. Downregulation of Decorin in ovarian cancer cells and colonization microenvironment drives progression

14. Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancer

15. Glycation‐Driven Impairment of Cytoskeletal Homeostasis and Viability Disables Glyoxalase‐Low Mesothelia From Resisting Cancer Colonization

16. MicroRNA-mediated resistance mechanisms in NAT-treated HER2-positive breast cancer (BC): A single centre retrospective analysis from matched primary and residual tumours

17. Complementary Role of Ancillary Tests in Acute Promyelocytic leukemia–A Case Series

18. Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancer

Languages Spoken

Book Appointment